HanAll Biopharma, NurrOn Pharmaceuticals and Daewoong Pharmaceutical have announced the dosing of the first human healthy subject in their Phase I clinical trial of Parkinson's disease (PD) therapy, HL192.

The trial will evaluate the pharmacokinetics, safety, tolerability and food effect of HL192 when given orally to healthy individuals aged between 18 and 80 years.

It will include both single ascending dose and multiple ascending dose cohorts.

The Phase I clinical trial’s initial results are projected to be revealed in the latter part of 2024.

HL192, which originated from NurrOn, is a first-in-class small molecule designed to activate Nurr1, which is a master regulator linked to the development and maintenance of dopaminergic neurons.

It showed potential as a disease-modifying agent by enhancing behavioural deficits in an animal model of PD.

HanAll, along with Daewoong, signed a co-development agreement with NurrOn to advance the therapeutic potential of HL192 across different neurodegenerative diseases.

NurrOn received a grant from The Michael J. Fox Foundation (MJFF) for Parkinson's Research to support the Phase I study.

HanAll Biopharma CEO Sean Jeong said: “HanAll, Daewoong and NurrOn share the common goal of developing transformative treatments for PD. Our collaboration has shown promise and we will continue to build on this joint effort.

“Today, we stand at a significant juncture, having achieved the start of our first-in-human trial for HL192. Having reached this key milestone, our next steps involve assessing HL192’s broader impact for patients with Parkinson’s disease globally as well as for other neurodegenerative conditions.”